Sirion advances two products into Phase III

June 14, 2007

Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

The programmes will evaluate ST-601 as a therapy for the treatment of anterior uveitis and ST-603 as a potential therapy for dry eye syndrome.

The addition of these two Phase III studies brings the number of Sirion's active clinical programmes to five.